Recruiting Glaucoma Studies in Phoenix
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT)....
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG)....
About Glaucoma Clinical Trials in Phoenix
Glaucoma is a group of eye conditions that damage the optic nerve, often due to abnormally high eye pressure, and is a leading cause of irreversible blindness. Open-angle glaucoma is the most common form. Treatment includes eye drops, laser treatment, and surgery to lower eye pressure.
There are currently 2 glaucoma clinical trials recruiting participants in Phoenix, ARIZONA. These studies are seeking a combined 520 participants. Research is being sponsored by Alcon Research, Amydis Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Glaucoma Clinical Trials in Phoenix — FAQ
Are there glaucoma clinical trials in Phoenix?
Yes, there are 2 glaucoma clinical trials currently recruiting in Phoenix, ARIZONA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Phoenix?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.
Are clinical trials in Phoenix free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.
What glaucoma treatments are being tested?
The 2 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for glaucoma.
Data updated March 2, 2026 from ClinicalTrials.gov